Skip to main content

Pegzilarginase FDA Approval Status

FDA Approved: No
Generic name: pegzilarginase
Company: Aeglea BioTherapeutics, Inc.
Treatment for: Arginase 1 Deficiency

Pegzilarginase is a novel, recombinant human arginase 1 enzyme replacement therapy in development for the treatment of Arginase 1 Deficiency (ARG1-D).

Development timeline for pegzilarginase

Apr 12, 2022Aeglea BioTherapeutics Submits BLA to FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency
Oct  1, 2018FDA Grants Rare Pediatric Disease Designation to Pegzilarginase for Arginase 1 Deficiency

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.